Novavax Inc. (NASDAQ:NVAX) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 17, Citi initiated ...

Buying shares of beaten-down companies only makes sense if there are good reasons to expect them to bounce back. If that's not the case, stocks that may look cheap and attractive aren't actually so.

The U.S. Centers for Disease Control and Prevention has ended its emergency response to the H5N1 bird flu outbreak, a move ...

Pfizer's COVID vaccine (Comirnaty) is fully approved for patients ages 12 and up, and authorized for kids ages 6 months ...

The FDA's Dr. Vinay Prasad said that he disagreed with the agency's career vaccine reviewers about COVID shot approvals.

Novavax Inc. closed 60.47% below its 52-week high of $17.81, which the company achieved on July 26th.

The stock's fall snapped a three-day winning streak.

Novavax expects revenue of $4 billion to $5 billion this year in global sales, Trizzino said, noting "this is not just a pandemic question, it's an ongoing vaccination question." ...

For many, Novavax is #1 – the one and only COVID vaccine they would consider. This enthusiasm for Novavax isn’t new. As far back as 2022, news reports described a kind of Novavax fan club ...

The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...

Novavax COVID vaccine will still save lives, experts say, even with limited supply. There are still more than 26 million American adults who are unvaccinated.

Novavax was authorized by the FDA for use in adults and children 12 and older, so younger kids can't get this vaccine. But for most adults, which COVID vaccine you should choose depends on your ...